⇨ Novartis said on Thursday that Kisqali (ribociclib) had been OK’d by EU regulators for frontline breast cancer, setting up a direct rivalry with Pfizer’s Ibrance. That’s another boost for Novartis’ critical oncology group.
⇨ Samsung Bioepis has claimed bragging rights as the first of the biosimilars makers to land an EU approval for all three anti-TNF-α blockbusters. The OK for its Humira knockoff just landed and the Korean company won approval for copycats of Enbrel and Remicade last year.
⇨ Switzerland’s Auris Medical $EARS is being spanked for noncompliance by Nasdaq again. With equity of $5.6 million, the biotech — whose lead drug flopped in a Phase III for tinnitus a year ago — doesn’t measure up to the exchange’s listing standards. The biotech has some time to work on it.
⇨ USC is joining up with a non-profit group to see if a regional alliance will give the area some of the major hub rep shared by the Bay Area and Boston/Cambridge. Southern California is something of an also-ran in the biopharma world, though it is home to quite a few biotechs, and the big players want to step up to global status.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 25,000+ biopharma pros who read Endpoints News by email every day.Free Subscription